Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Sep;66(9):1175-82.
doi: 10.1016/j.apradiso.2008.01.012. Epub 2008 Jan 26.

Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors

Hiroaki Kurihara  1 , David J Yang, Massimo Cristofanilli, William D Erwin, Dong-Fang Yu, Saady Kohanim, Richard Mendez, E Edmund Kim
Affiliations
Clinical Trial

Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors

Hiroaki Kurihara et al. Appl Radiat Isot. 2008 Sep.

Abstract

Background: Early detection of cellular events is important to predict the outcome of the patients. This study was aimed to use (99m)Tc EC-annexin V to image tumor cells undergoing apoptosis.

Methods: In 10 patients with breast cancer, scintigraphic images and dosimetric estimates were obtained after administering (99m)Tc EC-annexin V.

Results: Nine of the 10 cases showed detectable (99m)Tc EC-annexin V uptake in tumor. Higher values of T/N ratios are associated with patient after treatment.

Conclusions: Apoptosis can be quantified using (99m)Tc EC-annexin V.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Synthesis of 99mTc EC-Annexin V
FIGURE 2
FIGURE 2
High performance liquid chromatographic (HPLC) analysis of 99mTc EC-Annexin V (top: radioactive detector, bottom: UV detector at 254 nm) showed that radiochemical purity was >99%.
FIGURE 3
FIGURE 3
Axial images of patients who received 99mTc EC-annexin V (925-1073MBq, iv, 3 hours) showed that the tumors could be well visualized. Cross-line indicates ROI of tumor, and black circle indicates ROI of control. One patient showed high uptake in the lung, indicating colloid formation (case #7, image not shown).
FIGURE 4
FIGURE 4
Typical images of patients after treatment and without treatment. Crossed line indicates tumor location. The higher T/N ratio was obtained in the case of after treatment (case 4) as compared to the untreated case (case 9).
FIGURE 5
FIGURE 5
Tumor-to-non tumor count density (T/N) ratios with and without treatment. The mean value of T/N ratio with treatment was 2.6±0.5, significantly higher than that of without treatment (1.5±0.2).
See this image and copyright information in PMC

References

    1. Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98(6):1150–60. - PubMed
    1. Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. The Lancet. 2001;358(9278):277–86. - PubMed
    1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–2685. - PubMed
    1. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165–74. - PubMed
    1. Green MC, Buzdar AU, Smith T, et al. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. Journal of Clinical Oncology. 2005;23(25):5983–5992. - PubMed

Publication types

Substances